$4.85 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 127 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
PMVP | Exit | PMV PHARMACEUTICALS INC | $0 | – | -470 | -100.0% | 0.00% | – |
BCAB | Exit | BIOATLA INC | $0 | – | -289,002 | -100.0% | -0.03% | – |
AMWL | Exit | AMERICAN WELL CORPcl a | $0 | – | -391,115 | -100.0% | -0.04% | – |
Exit | NEOGENOMICS INCnote 0.250% 1/1 | $0 | – | -2,500,000 | -100.0% | -0.04% | – | |
GKOS | Exit | GLAUKOS CORPcall | $0 | – | -45,200 | -100.0% | -0.06% | – |
CGEM | Exit | CULLINAN ONCOLOGY INC | $0 | – | -375,585 | -100.0% | -0.09% | – |
VINC | Exit | VINCERX PHARMA INC | $0 | – | -1,379,310 | -100.0% | -0.12% | – |
Exit | BENEFITFOCUS INCnote 1.250%12/1 | $0 | – | -6,500,000 | -100.0% | -0.14% | – | |
TERN | Exit | TERNS PHARMACEUTICALS INC | $0 | – | -2,345,959 | -100.0% | -0.16% | – |
KALV | Exit | KALVISTA PHARMACEUTICALS INC | $0 | – | -830,472 | -100.0% | -0.27% | – |
SWTX | Exit | SPRINGWORKS THERAPEUTICS INC | $0 | – | -249,988 | -100.0% | -0.32% | – |
Exit | OAK STR HEALTH INCnote 3/1 | $0 | – | -18,000,000 | -100.0% | -0.32% | – | |
BCRX | Exit | BIOCRYST PHARMACEUTICALS INC | $0 | – | -1,012,000 | -100.0% | -0.37% | – |
NUVB | Exit | NUVATION BIO INC | $0 | – | -3,577,233 | -100.0% | -0.42% | – |
GDRX | Exit | GOODRX HLDGS INC | $0 | – | -979,106 | -100.0% | -0.42% | – |
MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -270,000 | -100.0% | -0.50% | – |
Exit | BRIDGEBIO PHARMA INCnote 2.500% 3/1 | $0 | – | -80,000,000 | -100.0% | -1.06% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
EHEALTH INC | 25 | Q3 2020 | 2.0% |
INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
MYLAN NV | 23 | Q3 2020 | 6.2% |
PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
3 | 2024-03-19 |
4 | 2024-03-19 |
4 | 2024-03-12 |
3 | 2024-03-08 |
4 | 2024-02-16 |
13F-HR | 2024-02-14 |
4 | 2024-02-08 |
3 | 2024-02-01 |
4 | 2023-11-21 |
13F-HR | 2023-11-14 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.